Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Ovarian Cancer Drug Resistance

  • Maria Paola Costi
  • John A. Green
  • Stefania Ferrari
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6990-5



Ovarian cancer is responsible for 4 % of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, and around 80 % of ovarian cancer patients initially achieve complete remission after primary treatment. However, the majority will relapse and eventually develop resistance to chemotherapy.


Standard chemotherapy comprises drugs based on the platinum complexes (carboplatin/cisplatin) which are either given as a single agent or in combination with the taxane paclitaxel. The chemotherapeutic activity of platinum drugs is mainly based on their ability to form DNA adducts and in particular the 1,2-d(GpG) intrastrand cross-link. Here, the platinum coordinates the N7 atoms of adjacent guanosines in the DNA strand and is poorly repaired in cells, with persistence of the lesion ultimately interfering with replication and transcription leading to cell death (Fig. 1). Drug resistance is a polygenic...


Ovarian Cancer Hepatocyte Growth Factor Epithelial Ovarian Cancer PARP Inhibitor Platinum Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Agrawl R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502–516. Available from http://www.nature.com/nrc/journal/v3/n7/full/nrc1123.html
  2. Cooke SL, Ng CKY, Melnyk N, Garcia MJ, Hardcastle T, Temple J, Langdon S, Huntsman D, Brenton JD (2010) Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29:4905–4913. Available from http://www.nature.com/onc/journal/v29/n35/full/onc2010245a.html
  3. Kaye SB (2008) Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26(16):2616–2618. Available from http://jco.ascopubs.org/content/26/16/2616.long CrossRefPubMedGoogle Scholar
  4. Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D (2008) Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 1:59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19038057 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Moore RG, McMeekin DS, Brown AK, Di Silvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40–46. Available from http://www.ncbi.nlm.nih.gov/pubmed/18851871 CrossRefPubMedGoogle Scholar
  6. Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF (2006) Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther 5:1126–1135. Available from http://www.ncbi.nlm.nih.gov/pubmed/167317447 CrossRefPubMedGoogle Scholar
  7. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R (2011) Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10:325–335. Available from http://www.ncbi.nlm.nih.gov/pubmed/21216927 CrossRefPubMedPubMedCentralGoogle Scholar
  8. Yap TA, Carden CP, Kaye SB (2008) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9:167–181. Available from http://www.nature.com/nrc/journal/v9/n6/abs/nrc2644.html CrossRefGoogle Scholar
  9. Zeller C, Brown R (2010) Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther Adv Med Oncol 2(5):319–329. Available from http://tam.sagepub.com/content/2/5/319 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Maria Paola Costi
    • 1
  • John A. Green
    • 2
  • Stefania Ferrari
    • 1
  1. 1.Department of Pharmaceutical SciencesUniversity of Modena and Reggio EmiliaModenaItaly
  2. 2.Department of Cancer MedicineUniversity of LiverpoolLiverpoolUK